Ceftriaxone: clinical application and production overview of broad-spectrum antibiotics

Ceftriaxone is a representative drug of the third generation cephalosporin antibiotics. It has the characteristics of broad-spectrum antibacterial, long-lasting effect and high safety. It is mainly used to treat infections of the respiratory tract, urinary system, skin and soft tissues caused by sensitive bacteria. This article will start from the pharmacological properties, indications, precautions for use and market production status, focusing on analyzing its clinical value and principles of rational drug use.

Pharmacological properties and core advantages

Ceftriaxone exerts a bactericidal effect by inhibiting bacterial cell wall synthesis and has good effects on both Gram-positive and Gram-negative bacteria, and is especially sensitive to common pathogenic bacteria such as Streptococcus pneumoniae and Escherichia coli. Its half-life is as long as 6-9 hours, allowing single daily administration, significantly improving patient compliance. Studies have shown that the drug has high concentrations in cerebrospinal fluid and is a first-line option for treating bacterial meningitis (Data source: "Fever: Sanford Guidelines for Antimicrobial Treatment").

Indications and clinical usage specifications

Ceftriaxone is suitable for moderate to severe infections, such as community-acquired pneumonia, complicated urinary tract infections, and perioperative prophylaxis. People who are allergic to penicillin should be aware of the risk of cross-allergy, and their liver function should be monitored during medication. China's "Guiding Principles for Clinical Application of Antimicrobial Drugs" emphasizes that medication should be adjusted strictly in accordance with bacterial culture results to avoid abuse leading to drug resistance.

Production status and market structure

Summary and suggestions for rational medication use

Ceftriaxone is an important clinical anti-infective weapon and needs to be used in a standardized manner under the guidance of a doctor. It is not effective against viral infections such as the common cold, and abuse may disrupt the balance of intestinal flora. Medical institutions should refer to the WHO's antimicrobial drug classification management requirements and classify them as restricted-use drugs to ensure a balance between efficacy and safety.

Quote sources:
1. "Fever: Sanford Guide to Antimicrobial Treatment" (52nd edition)
2. National Health Commission's "Guiding Principles for Clinical Application of Antimicrobial Agents (2015 Edition)"
3. WHO Essential Medicines List (2023)
4. Public information on the official website of pharmaceutical manufacturers